NOS is a Portuguese media holding company whose main assets include a satellite, cable operator, and ISP, a mobile phone operator, a movie distributor and a virtual carrier of mobile phone services. Its services include cable television, cable internet and VOIP. NOS is the spun-off media arm of Portugal Telecom. NOS produces several premium channels for the TV platform, which include SportTV and TVCine. NOS Audiovisuais is also the home-video distributor of Walt Disney Pictures, Warner Bros., DreamWorks and Paramount Pictures releases in the Portuguese market, alongside of launching several independent and European titles. Wikipedia.
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: HCO-02-2014 | Award Amount: 2.03M | Year: 2015
J-AGEII, the Coordination Action for implementation and alignment activities of the Joint Programming Initiative (JPI) More Years Better Lives the Challenges and Opportunities of Demographic Change, will support and foster the overall management of the JPI, update the Strategic Research Agenda and support implementation through joint activities between Member States. Furthermore, the work plan will include dissemination and information exchange with scientific and societal stakeholders, policy makers and research funders as well as an evaluation and monitoring exercise. Ultimately, the project and the JPI seek to stimulate the alignment of relevant national programmes and EU initiatives, strengthen the base of multi-disciplinary and holistic ageing research in Europe and to provide scientific evidence for policy responses to demographic change.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-12-2015 | Award Amount: 23.81M | Year: 2015
Antibiotic resistance is a global problem. It is considered by the World Health Organization as one of the three greatest threats to human health for the next decades. Enhanced coordination across national boundaries is needed to accelerate the efforts to tackle this grand challenge. Such synergies have been created among 19 countries in Europe and beyond through the EU JPI on Antimicrobial Resistance (JPIAMR). JPIAMR has developed a Strategic Research Agenda (SRA) which defines the strategic and scientific priorities benefiting from co-ordination and co-operation at the European level and mobilised national funds for two joint transnational calls (JTC) 2014 and 2015 based on this. In the ERA-NET Cofund JPI-EC-AMR, an additional 23 million of national funds will be combined with a highly incentivising EC top-up fund to support a new transnational research programme. The aim of this programme is to unravel the complex dynamics of selection and transmission of antimicrobial resistance (AMR) according to the One Health concept. A multidisciplinary approach is necessary to identify and characterise the determinants that contribute to the spread of resistance at genetic, bacterial, animal, human, societal, and environmental levels, in order to provide scientific knowledge to design and evaluate cost-effective strategies that can decrease transmission of AMR in society. JPI-EC-AMR will launch additional JTCs without EC co-funding under the framework of the SRA. and perform additional joint actions in close collaboration with JPIAMR actions. JPI-EC-AMR will provide a better, quantitative understanding of drug-resistant bacteria in animals, foods, and the environment and to what extent they contribute to the burden of antibiotic-resistant infections in humans. Research in this area is crucial in order to provide the robust scientific evidence needed to make informed decisions regarding interventions and policy measures in hospital, community, and agricultural settings.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-09-2014 | Award Amount: 14.78M | Year: 2015
Systems medicine is a new approach which integrates biological and medical data with mathematical and computational modelling in order to understand the underlying mechanisms of disease and to develop new strategies for individualised diagnosis, treatment and prevention. Systems medicine can fill the gap between experimental data produced by modern technologies and medical knowledge. Through the implementation of systems biology approaches in both clinical research and medical practice systems medicine will provide a new tool to clinicians that will change the capabilities of the clinician to diagnose and treat patients faster, better and more effectively a tool, which has the potential to become a generic prerequisite for any personalized or P4 medicine approach. The central idea of ERACoSysMed is to implement systems biology approaches in medical concepts, research and practice by structuring, coordinating and integrating national efforts and investments during its project duration of five years. To achive this main goal the specific objectives of ERACoSysMed are: 1) Strengthen the systems medicine community both across national borders as well as across specific research areas 2) Establish a network of funding bodies to sustainably implement systems medicine across Europe 3) Launch joint trans-national research calls with the aim to push forward the desired paradigm shift towards P4 medicine 4) Provide a platform for the implementation of the actions recommended by the CASyM road map For this aim Joint transnational calls (JTCs) for research proposals will be implemented. As a first step a co-funded JTC call will be launched with the aim to select transnational research projects in a competitive approach that shall demonstrate the social and economic benefit of the systems medicine approach. The consortium intends to implement further JTCs and other networking activities in order to keep alive the momentum which will be created by the co-funded JTC.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: ISIB-12f-2015 | Award Amount: 15.59M | Year: 2016
ERA-HDHL is a proposal of ERA-NET Cofund in the field of nutrition and health to support the Joint Programme Initiative Healthy Diet for a Healthy Life (JPI HDHL). Nowadays, there is a high burden of non-communicable diseases due to unhealthy diet and lifestyle patterns. The 24 members of the JPI HDHL are working together to develop means to (1) motivate people to adopt healthier lifestyles including dietary choices and physical activity, (2) develop and produce healthy, high-quality, safe and sustainable foods and (3) prevent diet-related diseases. Between 2012 and 2015, JPI HDHL had implemented 7 JFAs with 40 M funds from national funding. The JPI HDHL is now set for further enhancement in tight coordination with the EC through the ERA-NET Cofund instrument. ERA-HDHL will provide a robust platform for implementing joint funding actions (JFAs) that address the needs identified in the JPI HDHL strategic research agenda and strengthen the research funding activities of JPI HDHL. An EC cofunded call on the identification and validation of biomarkers in nutrition and health will be implemented. For this foreseen action, the member countries of the JPI HDHL have doubled their financial commitment comparing to previous JFA implemented on a similar topic. Moreover, ERA-HDHL will launch at least 3 additional JFAs in line to fulfil the JPI HDHL objectives.
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: HCO-17-2015 | Award Amount: 2.04M | Year: 2015
The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimers (JPND). Since 2009 JPND has been operating on a very light management structure based on a simple Terms of Reference. Through this JPND has been able to set a common Strategic Research Agenda, and to deliver its first implementation plan that has allowed among other achievements, the mobilisation of approximately 100 million of additional funding between 2011 and 2015 to support transnational research programs. While progress has been pleasing to date, the implementation of JPND must now be scaled-up to further catalyse Member State commitments, and to formalize synergies between members and various partners. The immediate challenge therefore for JPND is to secure its long-term sustainability by Member States, to mobilize those which are not yet participating, and to increase its impact at the national level and globally. JPsustaiND thus aims at creating the dedicated structure responsible for long-term JPND management and implementation, and extension of JPND membership to EU Member States and other countries and initiatives not yet participating. To achieve this goal, the JPsustaiND partners, with the support of the JPND Management Board, will implement the following six workpackages: Coordination and Management; Long Term Sustainability; Capacity Extension; Alignment and Outreach; Communication and Advocacy; and Monitoring, Evaluation and Impact Assessment. JPsustaiND will implement a stronger global dimension of the JPND, and will avoid duplication of research and infrastructure investment at the national level. By supporting further coordination and integration of national research and innovation programmes with the JPND research strategy, in coherence with Horizon 2020 objectives, JPsustaiND is thus creating a dedicated European Research Area for neurodegenerative diseases.